ArticleOrganic & biomolecular chemistry2014
The first synthesis of the antiangiogenic homoisoflavanone, cremastranone.
Article in Organic & biomolecular chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Exploring the Antiangiogenic and Anti-Inflammatory Potential of Homoisoflavonoids: Target Identification Using Biotin Probes.Biomolecules · 2024Review
- Cremastranone-Derived Homoisoflavanes Suppress the Growth of Breast Cancer Cells via Cell Cycle Arrest and Caspase-Independent Cell Death.Biomolecules & therapeutics · 2023Article
- Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease.The Journal of pharmacology and experimental therapeutics · 2023Review
- Bio-Prospecting of Crude Leaf Extracts from Thirteen Plants of Brazilian Cerrado Biome on Human Glioma Cell Lines.Molecules (Basel, Switzerland) · 2023Article
- Synthetic Homoisoflavane Derivatives of Cremastranone Suppress Growth of Colorectal Cancer Cells through Cell Cycle Arrest and Induction of Apoptosis.Biomolecules & therapeutics · 2022Article
- Mouse Pharmacokinetics and In Vitro Metabolism of SH-11037 and SH-11008, Synthetic Homoisoflavonoids for Retinal Neovascularization.Pharmaceutics · 2022Article
- Redox-neutral and metal-free synthesis of 3-(arylmethyl)chroman-4-onesFrontiers in chemistry · 2022Article
- Ferrochelatase regulates retinal neovascularization.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- Pharmacological Potential of Small Molecules for Treating Corneal Neovascularization.Molecules (Basel, Switzerland) · 2020Review
- Article
- Bufadienolides and anti-angiogenic homoisoflavonoids from Rhodocodon cryptopodus, Rhodocodon rotundus and Rhodocodon cyathiformis.Fitoterapia · 2020Article
- Enantioselective Synthesis of Homoisoflavanones by Asymmetric Transfer Hydrogenation and Their Biological Evaluation for Antiangiogenic Activity.The Journal of organic chemistry · 2019Article
- The Antiangiogenic Activity of Naturally Occurring and Synthetic Homoisoflavonoids from the Hyacinthaceae ( sensu APGII).Journal of natural products · 2019Article
- Small molecule target identification using photo-affinity chromatography.Methods in enzymology · 2019Article
- Ferrochelatase is a therapeutic target for ocular neovascularization.EMBO molecular medicine · 2017Article
- Design, synthesis and biological evaluation of photoaffinity probes of antiangiogenic homoisoflavonoids.Bioorganic & medicinal chemistry letters · 2016Article
- Synthesis of Natural Homoisoflavonoids Having Either 5,7-Dihydroxy-6-methoxy or 7-Hydroxy-5,6-dimethoxy Groups.Molecules (Basel, Switzerland) · 2016Article
- A novel small molecule ameliorates ocular neovascularisation and synergises with anti-VEGF therapy.Scientific reports · 2016Article
- Synthesis and Biological Evaluation of Novel Homoisoflavonoids for Retinal Neovascularization.Journal of medicinal chemistry · 2015Article
- Natural product inhibitors of ocular angiogenesis.Experimental eye research · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
An antiangiogenic homoisoflavanone, cremastranone, was synthesized for the first time. This scalable synthesis, which includes selective demethylation, could be used to develop lead molecules to treat angiogenesis-induced eye diseases. Synthetic cremastranone inhibited the proliferation, migration and tube formation ability of human retinal microvascular endothelial cells, important steps in pathological angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.